May 2003
Volume 44, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2003
Electronic Monitoring System to Assess Patient Adherence in Pediatric Drug Studies
Author Affiliations & Notes
  • J.D. Bartlett
    Department of Optometry, Univ of Alabama at Birmingham, Birmingham, AL, United States
  • M. Voce
    Department of Optometry, Univ of Alabama at Birmingham, Birmingham, AL, United States
  • T.P. Than
    Department of Optometry, Univ of Alabama at Birmingham, Birmingham, AL, United States
  • M. Edmondson
    Valley Forge Pharmaceuticals, Inc., Irvine, CA, United States
  • G.D. Novack
    PharmaLogic Development, Inc., San Rafael, CA, United States
  • Footnotes
    Commercial Relationships  J.D. Bartlett, Valley Forge Pharmaceuticals C; M. Voce, None; T.P. Than, None; M. Edmondson, Valley Forge Pharmaceuticals E; G.D. Novack, Valley Forge Pharmaceuticals C.
  • Footnotes
    Support  Valley Forge Pharmaceuticals
Investigative Ophthalmology & Visual Science May 2003, Vol.44, 1930. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J.D. Bartlett, M. Voce, T.P. Than, M. Edmondson, G.D. Novack; Electronic Monitoring System to Assess Patient Adherence in Pediatric Drug Studies . Invest. Ophthalmol. Vis. Sci. 2003;44(13):1930.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: The purpose of this study is to assess the feasibility of using the MEMS® SmartCap® electronic monitoring system to measure patient adherence to a drug-dosing regimen in a pediatric clinical trial of an investigational topical ophthalmic medication. The SmartCap is an electronic cap to a medication bottle that houses dispensed medications. It is designed for use with oral multi-use pharmacy bottles, but was adapted for topical ophthalmic medications by placing the gel tube inside the pharmacy bottle. Methods: Pirenzepine is a relatively selective M1-muscarinic antagonist. Formulated as a preserved gel and dispensed in an ophthalmic tube, it is under investigation for topical ocular use to retard the progression of pediatric myopia. We conducted a double-masked, placebo-controlled study in children ages 9-12 years with myopia. As part of, but incidental to, the clinical study, subjects were given a MEMS SmartCap with their study medication. Its purpose was explained and its use demonstrated. At scheduled visits, data from the electronic monitors were collected and analyzed. Results: MEMS monitors were used by 19 subjects starting at the 11th to 15th month in the study (range: day 276 to 447) and continuing for an average of approximately 100 days. The average overall compliance (total number of doses taken divided by total number of doses prescribed) was 64% (range: 10% - 97%). The mean proportion of doses taken in the morning was 45.2 ± 8.5% (range: 29-58%), suggesting no predominate morning or evening compliance. The proportion of doses taken on any day of the week was approximately 14%, suggesting no large difference in weekday versus weekend compliance. Conclusions: Overall compliance was approximately 60% for ophthalmic medication dosing. Use of the MEMS SmartCap appears to be a feasible approach to assessing patient adherence in pediatric investigational drug studies.

Keywords: pharmacology • clinical (human) or epidemiologic studies: sys • clinical research methodology 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×